CAJ | 학술논문

目的：评价依达拉奉联合丁苯酞与单独应用依达拉奉治疗急性缺血性脑卒中的临床疗效和安全性。方法将83例急性缺血性脑卒中患者随机分为对照组43例和试验组40例。2组患者均予以抗血小板、降脂稳定斑块及降压改善微循环等基础治疗。对照组予以依达拉奉30 mg＋0．9％氯化钠100 mL静脉点滴，bid ×14 d；试验组在对照组的基础上，联合口服丁苯酞200 mg，tid ×14 d。治疗后，比较2组患者的临床疗效、神经功能缺损程度（ CSS）评分、日常生活活动能力量表（ ADL）评分及不良反应发生率。结果试验组和对照组临床总有效率分别为82．50％和76．74％（ P＞0．05），但试验组临床总有效率已出现高于对照组的趋势。治疗后，2组患者的CSS评分及ADL评分均较治疗前显著改善（P＜0．05），且试验组较对照组改善更为显著（P＜0．05）。试验组与对照组不良反应发生率分别为10．00％和4．65％（ P＞0．05）。结论依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床疗效确切，可显著改善患者的神经功能。
목적：평개의체랍봉연합정분태여단독응용의체랍봉치료급성결혈성뇌졸중적림상료효화안전성。방법장83례급성결혈성뇌졸중환자수궤분위대조조43례화시험조40례。2조환자균여이항혈소판、강지은정반괴급강압개선미순배등기출치료。대조조여이의체랍봉30 mg＋0．9％록화납100 mL정맥점적，bid ×14 d；시험조재대조조적기출상，연합구복정분태200 mg，tid ×14 d。치료후，비교2조환자적림상료효、신경공능결손정도（ CSS）평분、일상생활활동능역량표（ ADL）평분급불량반응발생솔。결과시험조화대조조림상총유효솔분별위82．50％화76．74％（ P＞0．05），단시험조림상총유효솔이출현고우대조조적추세。치료후，2조환자적CSS평분급ADL평분균교치료전현저개선（P＜0．05），차시험조교대조조개선경위현저（P＜0．05）。시험조여대조조불량반응발생솔분별위10．00％화4．65％（ P＞0．05）。결론의체랍봉연합정분태치료급성결혈성뇌졸중적림상료효학절，가현저개선환자적신경공능。
Objective To evaluate the clinical efficacy and safety of edaravone combined with butylphthalide in treatment of acute cerebral ischemic stroke.Methods Eighty-three patients with acute cerebral ischemic stroke in the department of neurology of the Leqing People′s Hospital. And the included 83 cases were randomly divided into treatment group ( n =40 ) and control group ( n =43 ) . All of the included patients were underwent treatment of anti -platelet and depressurization.Patients in the control group were also treated with edaravone 30 mg+0.9%sodium chloride 100 mL intravenous transfusion bid ×14 d. And patients in the treatment group were administered butylphthalide 200 mg po, tid ×14 d. After treatment, the clinical efficacy and neurological function between the two groups were evaluated. Results The total clinical efficacy was not statistical significant (82.50% vs 76.74%) between the two groups ( P>0.05) , but the treatment group had the trend of higher compared to control group.The neurological score of the two groups were all improved significantly (P<0.05).And the treatment group was superior to control group (P<0.05).The adverse incidence rate were 10.00% and 4.65% in the treatment and control group respectively with no statistical different (P>0.05).ConclusionEdaravonecombinedwithbutylphthalideintreatmentofacutecerebralischemicwas effective and safe.